Park occupier, Isogenica Ltd, a leader in the design and construction of innovative and highly diverse synthetic antibody libraries, today announced a new licensing deal with a top-25 global pharmaceutical company which specialises in immunology, oncology and immuno-oncology biopharmaceuticals. 

Under the terms of the agreement, Isogenica has granted its licensee licences to its family of llamdA™ VHH single-domain antibody libraries for the discovery, development and commercialisation of therapeutic products derived from these libraries. Isogenica is entitled to an upfront and annual licence payments. If antibodies are advanced into development, Isogenica is entitled to further commercial upfront, licence and downstream payments.

Adam Collier, Isogenica’s Director of Commercial Development commented: “This is a very significant deal for Isogenica, which further validates and endorses the company’s highly diverse family of synthetic camelid single-domain antibody (VHH) libraries as an excellent starting point for therapeutic antibody discovery.  We look forward to enabling existing and new partners to find novel, developable therapeutic candidates quickly and efficiently”.

View the full release via Isogenica's website here.